Comparing cost-effectiveness results for a vaccine across different countries worldwide: what can we learn?

ABSTRACT:

Introduction

Cost-effectiveness analysis (CEA) using country-specific thresholds tied to gross domestic product (GDP) might not be appropriate in countries with low healthcare investment and a high disease burden as a consequence.

Methods

Using data from previously published CEA of rotavirus vaccination across nine countries worldwide, we calculated the cost neutral price (Pn) for the new intervention that reflects the price resulting in no net increase in health care costs compared with the current situation, and the maximum price (Pm) obtained with an incremental cost-effectiveness ratio (ICER) at the threshold value of 1×GDP/capita.

Results

In countries with low GDP/capita, the paradoxical finding for rotavirus vaccination is that the Pm is much higher than in coun

SUBMITTER: Standaert B 

PROVIDER: S-EPMC4209096 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature